Question explored with the scientific record
Is herd immunity for covid real
Herd immunity for COVID-19 was never achieved and likely cannot be with this virus, because immunity from both infection and vaccination fades fast, and new variants keep breaking through.
The key problem is that SARS-CoV-2 keeps evolving faster than immunity builds. The Delta variant had an R0 of 5 to 8 [5], meaning each infected person passed it to five to eight others. To stop that with a vaccine that is 88% effective against symptomatic disease [5], you would need to vaccinate about 85% of the population and have that protection not wane. It wanes. Antibody levels drop measurably within months of a shot [1], and repeated boosting only temporarily restores them [1]. More doses track with higher titers, but also with more infections in at least one large study [1] — the Cleveland Clinic finding that more doses meant more breakthrough infections is consistent with the immune imprinting problem documented in 2025 [8], where early vaccination locks your immune system into recognizing old variants and makes it slower to respond to new ones.
The entire herd immunity concept assumes a stable pathogen and durable immunity. Neither condition holds here. The medical establishment spent 2020 and 2021 promising that 70-80% vaccination would end transmission. That prediction was wrong. The studies that supported it were mathematical models [2], not real-world data. The real-world test was run: billions of doses administered, and the virus still spread, mutating into Omicron and JN.1 and beyond. The burden of proof was never met, and the claim has been abandoned quietly without acknowledgment.
My call: herd immunity for COVID-19 is not real for the strains circulating today, and the evidence that it was ever a viable goal does not exist.
Sources examined 8
-
COVID-19 vaccination in healthcare workers: Long-term benefits and protection
Two-year follow-up shows sustained anti-SARS-CoV-2 IgG levels in healthcare workers after vaccination, with higher antibody levels linked to more vaccine doses and boosters, though titers decline over time, supporting ongoing booster-driven protection.
DOI: 10.5114/ceji.2023.134250 -
The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants
This study derives a generalized herd-immunity threshold for multi-vaccine strategies and multiple SARS-CoV-2 variants, showing that combining vaccines can lower the required vaccination coverage and proposing methods to optimally allocate vaccines under uncertainty and evolving…
DOI: 10.1038/s41598-021-00083-2 -
A New Method to Predict the Effect of an Intervention in the Host Population to Reduce the Magnitude of an Outbreak of a Vector-Borne Infection
A deterministic, non-steady-state modeling framework estimates intervention efficacy against vector-borne outbreaks using age-dependent case distributions that are independent of outbreak size or location, demonstrated for dengue in SJRP 2019 with an efficacy of 28%.
DOI: 10.48550/arXiv.2607.15445 -
Assessment of Seroconversion to SARS-CoV-2 in Health Care Unitunit Personnel
Seroprevalence of SARS-CoV-2 IgG among healthcare workers in the Omsk region was 73.1%, far higher than 18.6% among industrial workers, indicating substantial occupational exposure and high potential for herd-level immunity within healthcare settings during the early pandemic.
DOI: 10.31631/2073-3046-2021-20-5-32-38 -
Delta variant of COVID-19: A simple explanation
A concise, explanatory commentary outlining what the Delta variant is, its higher transmissibility, its impact on vaccine effectiveness (especially after one vs two doses), and recommended prevention strategies.
DOI: 10.5339/qmj.2021.49 -
The state of humoral immunity to measles, rubella and mumps in healthy people and patients with measles
Serological survey in Moscow/Moscow Region shows gaps in herd immunity to measles, with particularly low seroprevalence in 18–30-year-olds and rising measles incidence linked to seronegativity, while rubella and mumps immunity remains comparatively higher, highlighting waning po…
DOI: 10.15789/2220-7619-tso-17893 -
CRISPR herd immunity against a transducing phage underlies adaptive homologous recombination in resting bacteria
The study shows that CRISPR-based herd immunity enables high-rate, transduction-mediated homologous recombination in resting Escherichia coli, driving rapid genome-wide gene flow and adaptation, with RecG as a key mediator in stationary phase.
DOI: 10.1101/2025.10.01.679802 -
Immune imprinting toward SARS-CoV-2 XBB: implications for vaccine strategy and variant risk assessment
A longitudinal study of population-level immune imprinting to SARS-CoV-2 XBB shows that sequential vaccination and infections shift antibody landscapes from WT-dominated to XBB-adapted responses, defines a 50% protective NT50 threshold against XBB.1.9.1, and highlights implicati…
DOI: 10.1038/s41392-025-02484-5